CClinicalTrials.gg
Status unknownNCT03579797SDESUpdated Jul 9, 2018

Shanghai Diabetic Eye Study in Diabetics

An observational study in Diabetic Eye Diseases and Diabetic Retinopathy, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Status unknown at 1 site in China. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2018-07-09.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Observational

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
200,000
Ages
35 Years and older
Sex
All
01

Study summary

The purpose of the Shanghai Diabetic Eye Study (SDES) was to guide and regulate eye health screening of two hundred thousand people with diabetes in the communities in 16 districts in Shanghai, build up the ranks with the general practitioner as the backbone combined, and provide comprehensive, continuous, and dynamic information service to diabetic eye disease health management. We expect to form a "screening, finding, referral, follow-up and health management" diabetic eye disease working mode, integrate medical care and precaution closely, promote the classified management and referral, reduce the prevalence rate of diabetic eye disease, blindness and visual impairment of DR, and improve diabetics consciousness of eye health maintenance. At the same time, we will also improve the device configuration of eye health screening and relevant personnel training mechanism in the community health service centers, thus upgrading the level of eye disease prevention and treatment in Shanghai.

Read the detailed description

Community-based cross-sectional samples of the archives management of adults with diabetes aged 35 years and above in 241 community health service centers (CHSC) in 16 districts in Shanghai, were obtained through proportional sampling (32%). Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. Field screening mainly included visual acuity assessment, autorefraction examination, and non-mydriatic fundus photography. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation of eye and general condition through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management

02

Conditions studied

  • Diabetic Eye Diseases
  • Diabetic Retinopathy

Keywords

  • diabetic eye diseases
  • diabetic retinopathy
03

In context

Retinal Diseases

815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.

This study's planned enrollment of 200,000 is above the median of 180 across 282 observational studies indexed under Retinal Diseases.

Browse Retinal Diseases studies →

Lead sponsor

Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 64 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Sampling was carried out in a proportional sampling plan that each diabetic under the archives management aged 35 years and above, residing in Shanghai.

Inclusion criteria

  • The target population included the adults with diabetes aged 35 years and above under archives management, residing in Shanghai.

Exclusion criteria

Exclusion Criteria:

  • \<35 years old;
  • Diabetics should not be able to move freely, clear-thinking and considered possible to cooperatively complete the ophthalmic examinations.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
200,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • BehavioralScreening, referral, follow-up and health management

    Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.

06

What researchers measure

Primary outcomes

  1. Diabetic retinopathy

    Prevalence of DR and diabetic macular edema. The DR grades are according to the well-accepted"International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale".

    Time frame: December 31, 2018

  2. Diabetic eye diseases

    Prevalence of eye diseases due to diabetes.

    Time frame: December 31, 2018

  3. Visual impairment

    Visual impairment was present if best corrected visual acuity \<20/25

    Time frame: December 31, 2018

  4. Glycosylated hemoglobin

    This test measure the average blood sugar control for the previous three months or so.

    Time frame: December 31, 2018

  5. Diabetics adherence to Diabetic Eye Diseases Study

    Predicting adherence in the research were obtained by Questionnaire for the study participants.

    Time frame: December 31, 2018

  6. Diabetics satisfaction for the SDES

    Diabetics satisfaction for the screening study,the community health service centers (CHSC),and the designated medical institutions were obtained by Questionnaire for the study participants.

    Time frame: December 31, 2018

  7. Referral compliance

    Referral compliance of diabetics were obtained by Questionnaire and Shanghai eye health information service system for the study participants.

    Time frame: December 31, 2018

  8. Human resources and ophthalmic equipment resources

    Compared to human resources and ophthalmic equipment resources in the community health service centers (CHSC),and the designated medical institutions before and after the SDES by Questionnaire.

    Time frame: December 31, 2018

  9. Eye health management

    All the study participants will be recommended appropriate eye health management.

    Time frame: December 31, 2018

07

Study locations

1 of 1 sites recruiting
  • Shanghai Eye Disease Prevention & Treatment Center
    Shanghai, Jingan 380 Kangding Road, China
    • Zhu Xiaofeng, MM · Contact · 8613917916016
    • Zhu Xiaofeng, MM · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03579797
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Jiannan Huang (Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Disease Prevention and Treatment Center) — Principal investigator
First posted
Jul 9, 2018
Start date
Jan 1, 2015
Primary completion
Dec 31, 2018 (estimated)
Completion
Dec 31, 2018 (estimated)
Last update
Jul 9, 2018

Study contacts

Haidong Zou, MD,PhD
Contact
zouhaidong@263.net
8613311986528
Yi Xu, MD,PhD
Contact
xxy1982@hotmail.com
8613795235166
Haidong Zou, MD,PhD
study chair · Shanghai Eye Disease Prevention and Treatment Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion